Review
Pharmacology & Pharmacy
Xiaoli Pan, Junping Pei, Aoxue Wang, Wen Shuai, Lu Feng, Faqian Bu, Yumeng Zhu, Lan Zhang, Guan Wang, Liang Ouyang
Summary: This review provides an overview of the roles of the ERKs signaling pathway in cancer and the structure-activity relationships of small molecule inhibitors targeting ERKs. It offers important insights for drug design and optimization as well as potential therapeutic strategies to overcome drug resistance.
ACTA PHARMACEUTICA SINICA B
(2022)
Article
Plant Sciences
Sirima Boonjing, Sutthaorn Pothongsrisit, Onsurang Wattanathamsan, Boonchoo Sritularak, Varisa Pongrakhananon
Summary: Erianthridin, a compound isolated from Dendrobium formosum, has shown promising cytotoxic effects in non-small cell lung cancer cells by inducing apoptosis. Mechanistic studies indicate that erianthridin can modulate apoptosis-related protein markers and mediate apoptosis through the regulation of Bcl-2 family proteins. In vitro assays demonstrate the potential of erianthridin to suppress lung cancer cell proliferation.
Article
Pharmacology & Pharmacy
Yan Hu, Zhe Zhao, Yuan-Ting Liu, Ze-Cheng Xu, Jing-Yi Li, Zheng-Yu Yang, Yun-Qi Yang, Jia-Hui Zhang, Si-Yuan Qiu, Tao He, Yi-Ying Wu, Sha Liu
Summary: This study found that NITyr inhibits non-small cell lung cancer (NSCLC) by activating CB1 and CB2 receptors, involving the PI3K and ERK pathways. It inhibits cell proliferation, blocks the cell cycle, induces apoptosis, and inhibits migration.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Oncology
Aurimas Stulpinas, Matas Sereika, Aida Vitkeviciene, Ausra Imbrasaite, Natalija Krestnikova, Audrone V. V. Kalvelyte
Summary: Cell signaling manipulation is crucial for anticancer therapy, and the cell state determines the response to drugs. Therefore, understanding the relationship between cell state and therapeutic sensitivity is essential for the development of cancer treatments. Patient-derived ex vivo cell models show promise in translating research findings into clinical applications in the era of personalized medicine.
FRONTIERS IN ONCOLOGY
(2023)
Article
Oncology
Lingyi Fu, Ru Deng, Yuhua Huang, Xia Yang, Neng Jiang, Jing Zhou, Censhan Lin, Shilu Chen, Liyan Wu, Qian Cui, Jingping Yun
Summary: DGKA is upregulated in the metastatic lesions of NSCLC and correlated with poor survival. It interacts with SRC and FAK proteins and activates the DGKA/SRC/FAK complex, initiating downstream signaling pathways and promoting EMT and angiogenesis in NSCLC. DGKA knockdown or pharmacologic inhibition can suppress the metastasis of NSCLC cells.
Review
Biochemistry & Molecular Biology
Aaron C. Tan, Nick Pavlakis
Summary: The management of advanced lung cancer has been transformed by the identification of targetable oncogenic driver alterations, including ALK gene rearrangements. ALK tyrosine kinase inhibitors have become the first-line treatment options for advanced ALK rearranged NSCLC. However, drug resistance remains a challenge, and the role of anti-angiogenic therapy in ALK rearranged NSCLC needs further exploration.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cell Biology
Junlei Han, Jianping Hu, Fang Sun, Hongzhi Bian, Bingxiang Tang, Xiang Fang
Summary: miR-20a suppresses NSCLC growth by inhibiting the RRM2-mediated PI3K/Akt signaling pathway, serving as a potential tumor suppressor and molecular target for NSCLC treatment.
MOLECULAR AND CELLULAR BIOCHEMISTRY
(2021)
Article
Cell Biology
Pavitra K. Jadaun, Shuang Zhang, Marijke Koedam, Jeroen Demmers, Suvro Chatterjee, Johannes P. van Leeuwen, Bram C. van der Eerden
Summary: The research indicates that MUC1 plays a critical role in osteoblastogenesis under hypoxic conditions, regulating the protein composition and influencing the osteogenic and angiogenic potentials of bone cells.
JOURNAL OF CELLULAR PHYSIOLOGY
(2022)
Article
Oncology
Yaya Yu, Zhenzhen Xiao, Chenjing Lei, Changju Ma, Lina Ding, Qing Tang, Yihan He, Yadong Chen, Xuesong Chang, Yanjuan Zhu, Haibo Zhang
Summary: Non-small cell lung cancer (NSCLC) patients with EGFR mutation often develop resistance to EGFR-TKIs due to the activation of PI3K/AKT signaling pathway. Combination of BYL719 and gefitinib, inhibitors of PI3K and EGFR-TKI respectively, showed synergistic effects in EGFR-mutated NSCLC cells with PI3K/AKT activation, providing a promising therapeutic approach to overcome EGFR-TKIs resistance induced by PI3K/AKT activation.
Article
Oncology
Onsurang Wattanathamsan, Paninee Chetprayoon, Naphat Chantaravisoot, Piriya Wongkongkathep, Pithi Chanvorachote, Varisa Pongrakhananon
Summary: This study demonstrates that CAMSAP3 plays an intriguing role in lung carcinoma cell senescence-associated phenotypes through modulating p-ERK/cyclin D1 signaling pathway. CAMSAP3 knockout promotes senescence and G1 cell cycle arrest in lung cancer cells by downregulating p-ERK and cyclin D1 levels. Vimentin appears to be required as a scaffold for CAMSAP3-modulating ERK signaling in lung cancer cells.
Article
Oncology
Qiang Li, Dongmei Yu, Zhengyuan Yu, Qian Gao, Ruifang Chen, Lin Zhou, Rong Wang, Yan Li, Yulan Qian, Jun Zhao, Rafael Rosell, Min Tao, Yufeng Xie, Chun Xu
Summary: Our study demonstrates that upregulation of TIPE3 promotes the progression of human NSCLC significantly by activating 13-catenin, Snail1, and Slug transcriptional signaling via the AKT/ERK1/2-GSK313 axis. Therefore, TIPE3 may represent a potential therapeutic target for NSCLC.
TRANSLATIONAL LUNG CANCER RESEARCH
(2021)
Article
Oncology
Fen Wang, Feng Jin, Boran Cheng, Yue Zhang, Qing Zhou, Shubin Wang
Summary: The study showed that anlotinib monotherapy in aNSCLC patients has promising efficacy in the first-line setting, serving as an option for those ineligible for chemotherapy. Anlotinib combination therapy in a >= second-line setting displayed manageable toxicities and encouraging efficacy, suggesting a favorable application prospect.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2022)
Article
Oncology
Takafumi Fukui, Motoko Tachihara, Tatsuya Nagano, Kazuyuki Kobayashi
Summary: Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC) has made significant progress in recent years with the development of multiple tyrosine kinase inhibitors (TKIs) targeting ALK. Clinical trials of novel ALK-TKIs, angiogenesis inhibitors, immune checkpoint inhibitors, and chemotherapy are ongoing, and tissue and liquid biopsy are being explored as methods to investigate resistance mechanisms. This manuscript aims to provide information on these recent clinical trials and propose a treatment algorithm for ALK-rearranged advanced NSCLC.
Article
Cell & Tissue Engineering
Jie Zhou, Junying Yang, Yuan Dong, Yaru Shi, Endong Zhu, Hairui Yuan, Xiaoxia Li, Baoli Wang
Summary: Our study has for the first time established the direct role of OSMR in regulating osteogenic differentiation of marrow stromal progenitor cells through ERK-mediated autophagy signaling. OSMR thus contributes to bone homeostasis through dual regulation of osteoblasts and osteoclasts. It also suggests that OSMR may be a potential target for the treatment of metabolic disorders such as osteoporosis.
STEM CELL RESEARCH & THERAPY
(2022)
Article
Psychology, Developmental
Craig A. Erickson, Charles R. Tessier, Christina Gross, Ernest Pedapati, Logan K. Wink, Kelli C. Dominick, Rebecca C. Shaffer, Hilary Rosselot, Michael P. Hong, Andrew P. Bantel, Elizabeth Berry-Kravis, Paul S. Horn, Ryan Adams, John A. Sweeney
Summary: This study investigated the activity of ERK1/2 in autism spectrum disorder (ASD). The results showed that lymphocytic ERK1/2 activation was faster in individuals with ASD, and this was correlated with greater social impairment. The differences in ERK1/2 activation were more pronounced in younger individuals.
JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY
(2023)